Evaxion A/S ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.04next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Business Update and Financial Results | 19 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly18.4MTarget: Sufficient to fund operations into the second half of 2027
Annual Operating Cash Burn Annually14MTarget: Maintain strict cost control similar to 2025 levels (~$14 million)
EVX-01 Phase 2 Vaccine Target Precision Annually0.9Target: Elicit tumor-specific immune responses in all patients
Watch Items
- EVX-01 Phase 2 Three-Year Clinical Efficacy DataTrigger: Release of 3-year clinical results from the extension of the Phase 2 trial in advanced melanomaAction: Evaluate long-term clinical outcomes and immunogenicity findings to support partnership discussions
- EVX-04 AML Program Clinical ReadinessTrigger: Submission of regulatory application / IND filing for Phase 1 trial by year-end 2026Action: Monitor transition of EVX-04 from preclinical to clinical-stage development
- AI-Immunology Platform Expansion into Autoimmune DiseasesTrigger: Optimization of indication strategy in the autoimmune space in H2 2026Action: Assess platform versatility and potential for new target discovery collaborations
- Nasdaq Minimum Stockholders' Equity ComplianceTrigger: Mandatory Panel Monitor period following compliance restorationAction: Ensure stockholders' equity remains above the $2.5 million minimum threshold to avoid immediate delisting
Research as of 19 Jun 2026